Hikma Pharmaceuticals (LSE:HIK) Construction In Progress : £324 Mil (As of Dec. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Construction In Progress?

Hikma Pharmaceuticals's quarterly construction in progress declined from Dec. 2023 (£215 Mil) to Jun. 2024 (£0 Mil) but then increased from Jun. 2024 (£0 Mil) to Dec. 2024 (£324 Mil).

Hikma Pharmaceuticals's annual construction in progress declined from Dec. 2022 (£215 Mil) to Dec. 2023 (£215 Mil) but then increased from Dec. 2023 (£215 Mil) to Dec. 2024 (£324 Mil).

Hikma Pharmaceuticals Construction In Progress Historical Data

The historical data trend for Hikma Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Construction In Progress Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Construction In Progress

Get a 7-Day Free Trial

189.72

203.79

215.10

214.88

323.52

Hikma Pharmaceuticals Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Construction In Progress	Get a 7-Day Free Trial															215.10	-	214.88	-	323.52

Hikma Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Hikma Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines